This week in therapeutics

Indication	Target/mark- er/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Platelet/ endothelial cell adhesion molecule (PECAM1; CD31)	<p>A study in mice suggests that inhibiting PECAM1 could help treat advanced metastatic cancer. In mouse models of late-stage metastatic melanoma or breast cancer, an anti-PECAM1 mAb decreased the number of metastases compared with an antibody control ($p<0.0001$). In the same late-stage model of melanoma, a sixth dose of an anti-PECAM1 mAb lowered both metastatic load in the lung ($p=0.02$) and the number of ovarian metastases ($p<0.05$) and increased body weight ($p=0.004$) compared with only five doses of the mAb. Ongoing work includes testing anti-PECAM1 mAbs in additional preclinical models of metastatic cancer.</p> <p>SciBX 3(41); doi:10.1038/scibx.2010.1230 Published online Oct. 21, 2010</p>	Patented; exclusively licensed to Genomic Systems LLC	<p>DeLisser, H. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Oct. 4, 2010; doi:10.1073/pnas.1004654107 Contact: Robert Debs, California Pacific Medical Center, San Francisco, Calif. e-mail: debs@cpmcri.org</p>